CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of “Moderate Buy” from Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-two brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $74.40.

A number of equities research analysts have issued reports on CRSP shares. Bank of America reduced their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Truist Financial increased their target price on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Morgan Stanley increased their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a report on Friday, February 14th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Thursday, February 13th. Finally, The Goldman Sachs Group reduced their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $47.91 on Friday. The stock has a market capitalization of $4.11 billion, a P/E ratio of -10.96 and a beta of 1.67. The company has a 50 day moving average price of $42.25 and a 200 day moving average price of $46.04. CRISPR Therapeutics has a fifty-two week low of $36.52 and a fifty-two week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Research analysts forecast that CRISPR Therapeutics will post -5.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 4.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics during the 3rd quarter worth $40,000. Darwin Wealth Management LLC purchased a new position in CRISPR Therapeutics during the 3rd quarter worth $43,000. Highline Wealth Partners LLC purchased a new position in CRISPR Therapeutics during the 4th quarter worth $39,000. Western Pacific Wealth Management LP grew its position in CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares during the last quarter. Finally, Eastern Bank purchased a new stake in shares of CRISPR Therapeutics in the third quarter valued at about $70,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.